On This Page

What NPs should know about Mifegymiso

Mifegymiso is a combination of medications that is prescribed for the medical termination of early pregnancy. Nurse Practitioners (NPs) are legally authorized to prescribe it.

Before prescribing Mifegymiso, NPs must ensure they have the knowledge, skill and judgment to do so and can manage all possible outcomes of prescribing this medication.

Health Canada has set requirements for the pharmaceutical company that provides Mifegymiso to mitigate the risks associated with this medication. These include providing prescribers with a medication guide and consent forms to give to clients, as well as a 24-hour support line for clients. For more information, visit the Health Canada website. Also read the Mifegymiso product monograph.

NPs who will be prescribing Mifegymiso should consider completing the Non-Accredited Medical Abortion Training e-learning program developed for health professionals who are involved in prescribing and dispensing this medication:

When prescribing or dispensing medication, NPs are expected to apply the requirements outlined in the Nurse Practitioner and Medication standards.  

NPs who do not prescribe Mifegymiso are expected to refer clients who may require this medication to another NP or physician who is able to prescribe the medication. Since Mifegymiso can only be provided in early pregnancy, this referral should be timely. You can find the expectations for consultation and referral in the Nurse Practitioner practice standard. The Ethics standard outlines the expectations for when a nurses’ personal values conflict with a client’s wishes.

Additional Resources:

Page last reviewed July 18, 2017